Abstract
The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Blood Cell Count
-
Cyclophosphamide / administration & dosage
-
Humans
-
Lymph Nodes / pathology
-
Lymphoma, Non-Hodgkin / blood
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Pancytopenia / chemically induced*
-
Prednisone / administration & dosage
-
Red-Cell Aplasia, Pure / blood
-
Red-Cell Aplasia, Pure / chemically induced*
-
Rituximab
-
Treatment Outcome
-
Vidarabine / adverse effects*
-
Vidarabine / analogs & derivatives*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab
-
Vincristine
-
Cyclophosphamide
-
Vidarabine
-
fludarabine
-
Prednisone